Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

HER2-positive Breast Cancer Clinical Trial

Official title:

Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05511844
• Other study ID #: ORM-5029-01-001
• Status: Recruiting
• Phase: Phase 1
• Start date: October 3, 2022
• Est. completion date: October 2025

Study information

• Verified date: March 2024
• Source: Orum Therapeutics USA, Inc.
• Contact: Orum Therapeutics USA, Inc.
• Phone: 617-714-9597
• Email: ClinicalTrials[@]orumrx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 87
• Est. completion date: October 2025
• Est. primary completion date: April 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

KEY INCLUSION CRITERIA

• Have histologically confirmed advanced breast cancer that is HER2+ by In Situ Hybridization (ISH) and/or at least 1+ staining by Immunohistochemistry (IHC), determined at the institution.
• Participant is not a candidate for or would be unlikely to tolerate or derive significant clinical benefit from, appropriate standard-of-care therapy, or the participant declines standard-of-care therapy, or the participant did not tolerate standard-of-care therapy.
• Eastern Cooperative Oncology Group (ECOG) performance status =2.
• Evaluable disease (for participants in the Part 1 Dose Escalation) or measurable disease as per RECIST v1.1 (for participants in the Part 2 Dose Expansion).
• Acceptable organ function at Screening.
• Acceptable hematologic function at Screening.
• Adequate coagulation parameters at Screening.
• Female participants of childbearing potential must:

1. Have a negative pregnancy test (serum) at Screening.

2. Agree to use at least one highly effective form of contraception during study treatment and after the last dose of ORM-5029.

• Male participants with female partners of childbearing potential must:

1. Agree to use at least one highly effective form of contraception during study treatment and after the last dose of ORM-5029.

2. Refrain from donating sperm during their participation in the study and after the last dose of ORM-5029.

• Resolution of all toxicities of prior therapy or surgical procedures to baseline or Grade 1 (except for neuropathy, which must have resolved to Grade =2, hypothyroidism requiring medication, and alopecia).
• Adequate cardiac left ventricular function, as defined by a left ventricular ejection fraction (LVEF) = institutional standard of normal.
• Life expectancy of =12 weeks according to the Investigator's judgment. KEY EXCLUSION CRITERIA
• Systemic antineoplastic agent or radiation therapy given within 14 days prior to the first dose of ORM-5029.
• Known sensitivity to any of the ingredients of ORM-5029, including previously reported infusion reactions to pertuzumab leading to pertuzumab treatment discontinuation.
• History of other malignancy within the last 2 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome.
• Symptomatic central nervous system (CNS) metastases or presence of leptomeningeal disease. Participant with previously treated brain metastases may participate.
• Pregnant or breastfeeding.
• Major surgery (excluding placement of vascular access) within 4 weeks prior to first dose of ORM-5029.
• Uncontrolled hypertension (systolic BP =160 mmHg; diastolic BP =100 mmHg) despite adequate treatment prior to the first dose of ORM-5029.
• Cardiac diseases currently or within the last 6 months as defined by New York Heart Association =Class 2.
• Mean resting QT interval corrected for heart rate (QTc) interval using the Fridericia formula (QTcF) >450 msec for males and >470 msec for females.
• Concurrent treatment with medications that are well-known to prolong the QT interval (see CredibleMeds website: https://www.crediblemeds.org/) unless a participant is QT stable on QT prolonging medication for at least 4 weeks.
• Severe dyspnea at rest, due to complications of advanced malignancy.
• Past medical history or complications of interstitial lung disease. Note: Participants with history of radiation induced interstitial lung disease may be enrolled if the participant's symptoms have recovered
• Active, uncontrolled bacterial, fungal, or viral infection, including known hepatitis B virus (HBV), known hepatitis C virus (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.

1. HIV Seropositive participants who are healthy and at low risk for AIDS-related outcomes can be considered eligible. HIV positive participants must be evaluated

and discussed with the Medical Monitor, and should have:

• CD4+ (cluster of differentiation 4) T-cell counts =350 cells/µL
• No prior history of AIDS-defining opportunistic infections
• Received established anti-retroviral therapy for at least four weeks and have an HIV viral load <400 copies/mL prior to enrolment.

2. Participants who are hepatitis B surface antigen positive are eligible if they have received HBV antiviral therapy for at least 4 weeks prior to the first dose of ORM-5029 and have undetectable HBV viral load prior to enrolment. Note: Participants must remain on antiviral therapy throughout study intervention and follow local guidelines for HBV antiviral therapy post completion of study intervention.

3. Participants with a history of HCV infection are eligible if they have received curative treatment and HCV viral load is undetectable prior to enrolment. Participants who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible. Note: Participants must have completed curative antiviral therapy at least 4 weeks prior to enrolment.

• Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of participants with Gilbert's Syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per Investigator assessment).
• Moderate or severe hepatic impairment (i.e., Child-Pugh class B or C).
• Any bleeding disorder (e.g., coagulopathy) or history of chronic bleeding and participants on therapeutic anticoagulant therapy during the treatment. Note: Participants on prophylactic anticoagulant therapy are considered eligible.
• Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction.

Related Conditions & MeSH terms

• HER-2 Gene Amplification
• HER-2 Protein Overexpression
• HER2 Gene Mutation
• HER2-positive Breast Cancer

Intervention

Drug:
• ORM-5029
Intravenous infusion

Locations

Country	Name	City	State
United States	University of Alabama Birmingham	Birmingham	Alabama
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	NEXT Oncology - Virginia Cancer Specialists	Fairfax	Virginia
United States	MD Anderson Cancer Center	Houston	Texas
United States	University of California - Los Angeles	Los Angeles	California
United States	Sarah Cannon Research Institute at Tennessee Oncology	Nashville	Tennessee
United States	Weill Cornell Medicine-New York	New York	New York
United States	Washington University	Saint Louis	Missouri
United States	NEXT Oncology	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Orum Therapeutics USA, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of Maximum Tolerated Dose (MTD) and Expansion Dose Level (EDL) [Dose Escalation Only]	Identify the Dose-limiting Toxicities (DLTs) for each dose level tested and determine the MTD and EDL for ORM-5029	DLT assessment period: At the end of Cycle 1 (each cycle is 21 or 28 days); Approximately 18 months for MTD and EDL
Primary	Incidence of Adverse Events (AEs)	Evaluate the safety and tolerability of ORM-5029 by identifying the treatment-emergent adverse events (TEAEs)	Every cycle (each cycle is 21 or 28 days) until study discontinuation; Approximately 30 months
Primary	Define the Objective Response Rate (ORR) of ORM-5029 based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 [Dose Expansion Only]	ORR is defined as the percentage of subjects with Partial Response (PR) or Complete Response (CR)	Approximately 30 months
Primary	Define the Duration of Response (DOR) of ORM-5029 based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 [Dose Expansion Only]	DOR is defined as the length of time from the date of the first documented response (PR or CR) until the date of first documented progression or date of death from any cause, whichever came first	Approximately 30 months
Secondary	Assess pharmacokinetic (PK) parameters including area under the concentration versus time curve from time 0 hours to the last quantifiable concentration (AUC0-last) and from time 0 hours to infinity (AUC0-inf)		Serial PK collections at on Days 1, 2, 4, 8 and 15 of Cycle 1 and Day 1 of Cycle 3 (Pre-dose and at multiple timepoints [up to 6 hours]; each cycle is 21 or 28 days)
Secondary	Assess maximum plasma and serum drug concentration (Cmax)		Serial PK collections at on Days 1, 2, 4, 8 and 15 of Cycle 1 and Day 1 of Cycle 3 (Pre-dose and at multiple timepoints [up to 6 hours]; each cycle is 21 or 28 days)
Secondary	Define time to Cmax (Tmax)		Serial PK collections at on Days 1, 2, 4, 8 and 15 of Cycle 1 and Day 1 of Cycle 3 (Pre-dose and at multiple timepoints [up to 6 hours]; each cycle is 21 or 28 days)
Secondary	Access pharmacokinetic (PK) parameters including terminal rate consent and terminal elimination half-life (t1/2)		Serial PK collections at Baseline, Days 2, 4, 8 and 15 of Cycle 1 and Day 1 of Cycle 3 (Pre-dose and at multiple timepoints [up to 6 hours]; each cycle is 21 or 28 days)
Secondary	Define Clinical Benefit Rate (CBR) of ORM-5029 based on RECIST 1.1	CBR is defined as CR + PR + stable disease (SD) up to 4 months	Approximately 30 months
Secondary	Define Time to Response (TTR) of ORM-5029 based on RECIST 1.1	TTR is defined as the length of time from baseline until the date of first documented response (PR or CR)	Approximately 30 months
Secondary	Define Duration of Response (DOR) of ORM-5029 based on RECIST 1.1 [Dose Escalation Only]	DOR is defined as the length of time from the date of the first documented response (PR or CR) until the date of first documented progression or date of death from any cause, whichever came first	Approximately 30 months
Secondary	Assess Progression-free survival (PFS) of ORM-5029 based on RECIST 1.1	PFS is defined as the length of time from baseline until the date of first documented progression or date of death from any cause, whichever came first	Approximately 30 months
Secondary	Assess overall survival (OS)		Following study discontinuation until withdrawal for any reason or death; Approximately 30 months
Secondary	Incidence of anti-drug antibody (ADA) against ORM-5029		Sample collection at Baseline, Day 1 of every Cycle until study discontinuation (each cycle is 21 or 28 days); Approximately 30 months